WO2017054786A1 - Procédé de production du 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-méthylpipéridine-4-yl)urée et de ses analogues deutérés - Google Patents
Procédé de production du 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-méthylpipéridine-4-yl)urée et de ses analogues deutérés Download PDFInfo
- Publication number
- WO2017054786A1 WO2017054786A1 PCT/CZ2016/000104 CZ2016000104W WO2017054786A1 WO 2017054786 A1 WO2017054786 A1 WO 2017054786A1 CZ 2016000104 W CZ2016000104 W CZ 2016000104W WO 2017054786 A1 WO2017054786 A1 WO 2017054786A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- accordance
- fluorobenzyl
- pimavanserin
- Prior art date
Links
- RKEWSXXUOLRFBX-UHFFFAOYSA-N CC(C)COc1ccc(CNC(N(Cc(cc2)ccc2F)C2CCN(C)CC2)=O)cc1 Chemical compound CC(C)COc1ccc(CNC(N(Cc(cc2)ccc2F)C2CCN(C)CC2)=O)cc1 RKEWSXXUOLRFBX-UHFFFAOYSA-N 0.000 description 1
- PLYWEOOWONUOBN-UHFFFAOYSA-N CN(CC1)CCC1NCc(cc1)ccc1F Chemical compound CN(CC1)CCC1NCc(cc1)ccc1F PLYWEOOWONUOBN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
Definitions
- the invention relates to an improved production method of l-(4-fluorobenzyl)-3-(4- isobutoxybenzyl)-l-(l— methylpiperidin-4-yl)urea of formula I, known under the generic name of pimavanserin.
- Pimavanserin is an inverse agonist of the serotonin 5-HT 2A receptor and is currently in the tartrate form in stage III of clinical trial for the treatment of psychosis in patients suffering from Parkinson's disease and has potential to become part of the therapy of other psychotic conditions.
- Pimavanserin of formula I is produced, according to the published patent applications (WO2004064738, WO2006036874, WO2006037043), from the input N-(4-fluorobenzyl)-l- methylpiperidine-4 ⁇ amine of formula II through a reaction with 1-isobutoxybenzyl isocyanate of formula III, providing crude pimavanserin (Diagram 1).
- the above mentioned methods of pimavanserin synthesis feature a number of disadvantages.
- the main disadvantages comprise the use of 4-isobutoxybenzyl isocyanate of formula III, which is, as all the substances of this type, toxic, unpleasantly malodorous and highly reactive.
- Another disadvantage is that the described methods of its synthesis either use the highly toxic phosgene, or the also toxic diphenyl phosphoryl azide (DPPA), which is additionally as all azides potentially explosive.
- DPPA diphenyl phosphoryl azide
- Partly deuterated analogs of pimavanserin are also described that exhibit, based on the kinetic isotope effect, lower sensitivity to metabolic degradation and can thus have the corresponding therapeutic advantages as a lower dosage, higher effect, lower inter-individual deviations and more (WO2008141057).
- their synthesis is analogous to the above mentioned methods described in the published patent applications WO2004064738, WO2006036874 and WO2006037043 with the use of partly deuterated input substances. Disclosure of the Invention
- the invention relates to a new efficient preparation method of highly pure l-(4-fluorobenzyl)-
- the invention relates to a new efficient preparation method of highly pure l-(4-fluorobenzyl)- 3-(4-isobutoxybenzyl)-l-(l-methylpiperidin-4-yl)urea - pimavanserin of formula I, which does not contain the amine of formula II, or the doubled impurity of formula IX.
- the method is based on the known 4-isobutoxybenzylamine of formula VII, which reacts with the reagent of formula X, preferably with ⁇ , -carbonyldiimidazole (CDI) of formula Xa, producing the correspondingly substituted N-(4-isobutoxybenzyl)-l -carbamide of formula XI.
- This reaction can be carried out in a number of solvents at an elevated temperature.
- Polar aprotic solvents of the ester or ether type are suitable, preferably tetrahydrofuran or 2-methyltetrahydrofuran.
- the reaction can be carried out at temperatures in the range from 40°C to the boiling point, preferably at 50 - 60°C.
- the heterocycle of formula XII falls off as a side product, which can be, together with the excess reagent of formula X, removed by washing with water, possibly with an addition of an inorganic base, preferably sodium carbonate, or an acid, preferably diluted hydrochloric acid.
- the obtained crude product can be repurified by crystallization from various solvents, preferably C2 - C4 alcohols with a straight or branched chain, preferably from isopropyl alcohol.
- the carbamide of formula XI obtained this way reacts with N-(4-fluorobenzyl)-l- methylpiperidine-4-amine of formula II in the second stage, producing l-(4-fluorobenzyl)-3- (4-isobutoxybenzyl)-l-(l-methylpiperidin-4-yl)urea - pimavanserin of formula I.
- the reaction can be carried out at temperatures in the range from 40°C to the boiling point, preferably at 50 - 60°C.
- the heterocycle of formula XII falls off as a side product, which can be removed by washing with water, possibly with an addition of an inorganic base, preferably sodium carbonate, or an acid, preferably diluted hydrochloric acid.
- the product can be obtained as a free base or as a salt with organic acids.
- the above mentioned reaction stages can be carried out either in two separate steps with isolation of the intermediate product of formula XI, or in a single step without isolation and purification.
- the mixture was further stirred at 60°C for 16 h, then the reaction mixture was washed with a 5% solution of sodium carbonate (2 x 100 ml) and water (1 x 100 ml). The organic phase was then evaporated on a vacuum evaporator, the amount of 9.33 g of the crude evaporation product was obtained. The evaporation product was recrystallized from isopropyl alcohol (50 ml), the amount of 8.5 g (67%) was obtained.
- N-(4-isobutoxybenzyl)-l H-imidazole- 1 -carbamide (XIa) 2.0 g; 7.32 mmol
- THF 25 ml
- N-(4-fluorobenzyl)-l-methylpiperidine-4-amine (II) 1.8 g; 8.05 mmol
- the mixture was diluted with MTBE (50 ml) and washed with a 5% solution of sodium hydrogen carbonate (1 x 50 ml) and water (2 x 50 ml).
- the organic phase was dried with magnesium sulfate and after removal of the drying agent by filtration evaporated until dry.
- the obtained evaporation product (3.3 g) was recrystallized from isopropyl alcohol (10 ml). The amount of 2.2 g of crystals (70%) was obtained.
- N-(4-fluorobenzyl)-l-methylpiperidine-4-amine (II) (8.2 g; 36.8 mmol) was added to the solution by dripping during 5 minutes and the mixture was further stirred for 2 h at 60°C.
- the reaction mixture was washed with 3.5% hydrochloric acid (1 x 70 ml, 1 x 20 ml) and subsequently with water (1 x 20 ml).
- the reaction mixture was subsequently washed with 3.5% hydrochloric acid (1 x 50 ml, 1 x 25 ml) and then with saturated salt brine (1 x 50 ml).
- the organic fraction was transferred to a flask and p- toluenesulfonic acid monohydrate (4.4 g; 23.2 mmol) in 2-methyltetrahydrofuran (25 ml) was added.
- the obtained turbid solution was evaporated until dry and the evaporation product (16.4 g) was dissolved in ethanol (120 ml).
- the hot ethanolic solution was filtered and after cooling and seeding the product crystallizes in the form of a salt.
- the amount of 9.5 g of the crystalline product was obtained (68%).
- the reaction mixture was washed with 3.5% hydrochloric acid (2 x 10 ml) and subsequently with water (1 x 10 ml).
- the organic fraction was evaporated until dry, the evaporation product was dissolved in isopropyl alcohol (10 ml) and a solution of p-toluenesulfonic hydrate (1.06 g; 5.58 mmol) in isopropyl alcohol (55 ml) was added to the solution obtained this way in a hot state.
- the mixture was slowly left to crystallize to the lab. , the separated crystalline fraction was removed by filtration and washed with ethyl methyl ketone. The amount of 2.31 g of the crystalline product was obtained (69%).
- the reaction mixture was washed with 3.5% hydrochloric acid (2 x 10 ml) and subsequently with water (1 x 10 ml).
- the organic fraction was evaporated until dry, the evaporation product was dissolved in isopropyl alcohol (10 ml) and a solution of p-toluenesulfonic hydrate (1.06 g; 5.58 mmol) in isopropyl alcohol (55 ml) was added to the solution obtained this way in a hot state.
- the mixture was slowly left to crystallize to the lab. t, the separated crystalline fraction was removed by filtration and washed with ethyl methyl ketone. The amount of 2.17 g of the crystalline product was obtained (65%).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne un procédé amélioré de production du 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-méthylpipéridine-4-yl)urée (pimavansérine), un agoniste inverse du récepteur 5-HT2A de la sérotonine de formule (I). La pimavansérine brute préparée par ce procédé contient une très faible quantité de l'impureté disubstituée.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CZ2015-688A CZ2015688A3 (cs) | 2015-10-02 | 2015-10-02 | Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jeho deuterovaných analogů |
CZPV2015-688 | 2015-10-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017054786A1 true WO2017054786A1 (fr) | 2017-04-06 |
Family
ID=57120970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CZ2016/000104 WO2017054786A1 (fr) | 2015-10-02 | 2016-09-14 | Procédé de production du 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-méthylpipéridine-4-yl)urée et de ses analogues deutérés |
Country Status (2)
Country | Link |
---|---|
CZ (1) | CZ2015688A3 (fr) |
WO (1) | WO2017054786A1 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107216271A (zh) * | 2017-06-02 | 2017-09-29 | 沈阳药科大学 | 酒石酸匹莫范色林杂质及其制备方法 |
WO2018007842A1 (fr) * | 2016-07-08 | 2018-01-11 | Egis Gyógyszergyár Zrt. | Sels de pimavansérine utiles pour l'élaboration d'une préparation pharmaceutique. |
WO2019008595A1 (fr) * | 2017-07-03 | 2019-01-10 | Jubilant Generics Limited (Formerly A Division Of Jubilant Life Sciences Limited) | Procédé pour la préparation de la 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-méthylpipéridin-4-yl)urée et de ses sels |
CN110054583A (zh) * | 2018-01-19 | 2019-07-26 | 广东东阳光药业有限公司 | 一种制备哌马色林或其盐的方法 |
WO2019179920A1 (fr) | 2018-03-19 | 2019-09-26 | Lundbeck Pharmaceuticals Italy S.P.A. | Procédé de fabrication de pimavansérine |
IT201800009690A1 (it) | 2018-10-23 | 2020-04-23 | Lundbeck Pharmaceuticals Italy Spa | Processo per la produzione di pimavanserina |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004064738A2 (fr) | 2003-01-16 | 2004-08-05 | Acadia Pharmaceuticals Inc. | Agonistes inverses selectifs pour le recepteur de la serotonine 2a/2c utilises comme agents therapeutiques contre les maladies neurodegeneratives |
WO2006036874A1 (fr) | 2004-09-27 | 2006-04-06 | Acadia Pharmaceuticals Inc. | Sels de n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide et leur preparation |
WO2008141057A1 (fr) | 2007-05-08 | 2008-11-20 | Auspex Pharmaceuticals, Inc. | Urées substituées |
WO2014085362A1 (fr) * | 2012-11-27 | 2014-06-05 | Acadia Pharmaceuticals Inc. | Méthodes pour le traitement de la psychose de la maladie de parkinson à l'aide de pimavansérine |
CN104844502A (zh) * | 2015-06-05 | 2015-08-19 | 济南涛瑞医药科技有限公司 | 一种匹莫范色林的制备方法 |
CN105111135A (zh) * | 2015-09-09 | 2015-12-02 | 安徽省逸欣铭医药科技有限公司 | 取代的尿素衍生物制备方法 |
CN105153016A (zh) * | 2015-10-12 | 2015-12-16 | 北京诺康达医药科技有限公司 | 一种匹莫范色林的制备方法 |
CN105820110A (zh) * | 2016-05-09 | 2016-08-03 | 杭州科巢生物科技有限公司 | 匹莫范色林新合成方法 |
WO2016141003A1 (fr) * | 2015-03-02 | 2016-09-09 | Teva Pharmaceutical Industries Ltd. | Procédés et intermédiaires pour la préparation de pimavansérine |
-
2015
- 2015-10-02 CZ CZ2015-688A patent/CZ2015688A3/cs unknown
-
2016
- 2016-09-14 WO PCT/CZ2016/000104 patent/WO2017054786A1/fr active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004064738A2 (fr) | 2003-01-16 | 2004-08-05 | Acadia Pharmaceuticals Inc. | Agonistes inverses selectifs pour le recepteur de la serotonine 2a/2c utilises comme agents therapeutiques contre les maladies neurodegeneratives |
WO2006036874A1 (fr) | 2004-09-27 | 2006-04-06 | Acadia Pharmaceuticals Inc. | Sels de n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide et leur preparation |
WO2006037043A1 (fr) | 2004-09-27 | 2006-04-06 | Acadia Pharmaceuticals Inc. | Synthese de n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide, tartrate de ce compose et ses formes cristallines |
WO2008141057A1 (fr) | 2007-05-08 | 2008-11-20 | Auspex Pharmaceuticals, Inc. | Urées substituées |
WO2014085362A1 (fr) * | 2012-11-27 | 2014-06-05 | Acadia Pharmaceuticals Inc. | Méthodes pour le traitement de la psychose de la maladie de parkinson à l'aide de pimavansérine |
WO2016141003A1 (fr) * | 2015-03-02 | 2016-09-09 | Teva Pharmaceutical Industries Ltd. | Procédés et intermédiaires pour la préparation de pimavansérine |
CN104844502A (zh) * | 2015-06-05 | 2015-08-19 | 济南涛瑞医药科技有限公司 | 一种匹莫范色林的制备方法 |
CN105111135A (zh) * | 2015-09-09 | 2015-12-02 | 安徽省逸欣铭医药科技有限公司 | 取代的尿素衍生物制备方法 |
CN105153016A (zh) * | 2015-10-12 | 2015-12-16 | 北京诺康达医药科技有限公司 | 一种匹莫范色林的制备方法 |
CN105820110A (zh) * | 2016-05-09 | 2016-08-03 | 杭州科巢生物科技有限公司 | 匹莫范色林新合成方法 |
Non-Patent Citations (1)
Title |
---|
PETAR A. DUSPARA ET AL: "Synthesis and Reactivity of N -Alkyl Carbamoylimidazoles: Development of N -Methyl Carbamoylimidazole as a Methyl Isocyanate Equivalent", THE JOURNAL OF ORGANIC CHEMISTRY, vol. 77, no. 22, 16 November 2012 (2012-11-16), US, pages 10362 - 10368, XP055269988, ISSN: 0022-3263, DOI: 10.1021/jo302084a * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018007842A1 (fr) * | 2016-07-08 | 2018-01-11 | Egis Gyógyszergyár Zrt. | Sels de pimavansérine utiles pour l'élaboration d'une préparation pharmaceutique. |
CN107216271A (zh) * | 2017-06-02 | 2017-09-29 | 沈阳药科大学 | 酒石酸匹莫范色林杂质及其制备方法 |
CN107216271B (zh) * | 2017-06-02 | 2018-11-13 | 沈阳药科大学 | 酒石酸匹莫范色林杂质及其制备方法 |
WO2019008595A1 (fr) * | 2017-07-03 | 2019-01-10 | Jubilant Generics Limited (Formerly A Division Of Jubilant Life Sciences Limited) | Procédé pour la préparation de la 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-méthylpipéridin-4-yl)urée et de ses sels |
CN110054583A (zh) * | 2018-01-19 | 2019-07-26 | 广东东阳光药业有限公司 | 一种制备哌马色林或其盐的方法 |
WO2019179920A1 (fr) | 2018-03-19 | 2019-09-26 | Lundbeck Pharmaceuticals Italy S.P.A. | Procédé de fabrication de pimavansérine |
IT201800009690A1 (it) | 2018-10-23 | 2020-04-23 | Lundbeck Pharmaceuticals Italy Spa | Processo per la produzione di pimavanserina |
WO2020083825A1 (fr) | 2018-10-23 | 2020-04-30 | Lundbeck Pharmaceuticals Italy S.P.A. | Procédé de fabrication de pimavansérine |
Also Published As
Publication number | Publication date |
---|---|
CZ2015688A3 (cs) | 2017-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017054786A1 (fr) | Procédé de production du 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-méthylpipéridine-4-yl)urée et de ses analogues deutérés | |
KR101593253B1 (ko) | 페닐 및 벤조디옥시닐 치환 인다졸 유도체 | |
JP6013326B2 (ja) | キラルトリアゾロンの調製のための方法 | |
JP2022023891A (ja) | オメカムチブメカルビルの塩及び塩を調製するプロセス | |
JP3560986B2 (ja) | 5―ht2c受容体作用薬及びアミノアルキルインダゾール誘導体 | |
CA2861150C (fr) | Derive de morphinane | |
UA128114C2 (uk) | Тверді форми 3-((1r,3r)-1-(2,6-дифтор-4-((1-(3-фторпропіл)азетидин-3-іл)аміно)феніл)-3-метил-1,3,4,9-тетрагідро-2h-піридo[3,4-b]індол-2-іл)-2,2-дифторпропан-1-олу і способи одержання конденсованих трициклічних сполук, що містять заміщене фенільне або піридинільне угруповання, в тому числі способи їх застосування | |
JP2014521726A5 (fr) | ||
TW201725207A (zh) | 一種btk激酶抑制劑的結晶形式及其製備方法 | |
HUE023239T4 (en) | Modulators of the prostacycline (PGI2) receptor that can be used to treat related diseases | |
EP2718262A1 (fr) | Procédé de préparation d'apixaban | |
JP2013532164A (ja) | トロンビン特異的インヒビターを調製する方法 | |
TW200538116A (en) | Process for the preparation of substituted triazole compounds | |
KR102266680B1 (ko) | 벨리노스테트의 다형태 및 이의 제조 방법 | |
US20090264438A1 (en) | Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form alpha | |
SK21596A3 (en) | Application of substituted aryloxyalkyl diamines, these substances single, producing method thereof, pharmaceutical compositions on their base and their producing method | |
JPWO2010107115A1 (ja) | グリシントランスポーター阻害物質 | |
BR112020018562A2 (pt) | Processo preparativo | |
AU781837B2 (en) | 3-azabicyclo (3.1.0) hexane derivatives having opioid receptor affinity | |
JP2002521334A (ja) | 置換ベンズイミダゾール抗ウィルス剤 | |
JP2019509308A (ja) | 1−(5−(2,4−ジフルオロフェニル)−1−((3−フルオロフェニル)スルホニル)−4−メトキシ−1h−ピロール−3−イル)−n−メチルメタンアミン塩の新規な結晶形 | |
CZ216996A3 (en) | Indole derivatives, process of their preparation, their use and pharmaceutical compositions containing thereof | |
EA036954B1 (ru) | Ксантинзамещенные алкинилкарбаматы/обращенные карбаматы в качестве антагонистов a2b | |
RU2536688C2 (ru) | Новые бензамидные производные | |
KR20100046026A (ko) | 4-페닐-6-(2,2,2-트리플루오로-1-페닐에톡시)피리미딘-기재화합물의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16778669 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16778669 Country of ref document: EP Kind code of ref document: A1 |